Celcuity Reports the P-III (VIKTORIA-1) Trial Data on Gedatolisib Combination for HR+/HER2- PIK3CA Mutant Advanced Breast Cancer

Why It Matters

The data suggest a more effective PI3K‑targeted regimen for patients who have progressed after CDK4/6 inhibitors, potentially reshaping the treatment algorithm and accelerating market entry through priority review.

Key Takeaways

• Gedatolisib triplet outperformed alpelisib combo in PFS for PIK3CA mutants
• Secondary analysis showed gedatolisib + fulvestrant also improved PFS
• Results will be presented at ASCO 2026, raising clinical visibility
• Celcuity plans sNDA submission; FDA granted priority review
• PDUFA deadline set for July 17, 2026, expediting approval timeline

Pulse Analysis

The PI3K‑AKT‑mTOR axis remains a critical driver of resistance in hormone‑receptor‑positive, HER2‑negative breast cancer, especially after patients exhaust CDK4/6 inhibitors and aromatase inhibitors. While alpelisib, the first-in-class PI3Kα inhibitor, has offered modest gains, its safety profile and modest efficacy have left an unmet need for more potent and tolerable options. Gedatolisib, a dual PI3K/mTOR inhibitor, targets a broader spectrum of the pathway, positioning it as a compelling candidate to overcome resistance mechanisms that limit current therapies.

In the VIKTORIA‑1 phase‑III trial, the gedatolisib‑fulvestrant triplet, with optional palbociclib, delivered a clinically meaningful PFS extension compared with the alpelisib‑fulvestrant backbone. The primary endpoint was met, and a secondary analysis confirmed that even the doublet without palbocicline retained a PFS advantage. These findings, slated for presentation at ASCO 2026, underscore gedatolisib’s potential to become a new standard for the PIK3CA‑mutant cohort, offering oncologists a more robust option to delay disease progression.

Regulatory momentum is strong: the FDA has granted priority review for gedatolisib in the PIK3CA‑wild‑type setting, with a PDUFA action date of July 17, 2026. Celcuity’s planned sNDA submission leverages the VIKTORIA‑1 data to seek broader labeling. If approved, gedatolisib could capture significant market share from alpelisib, especially given its dual inhibition profile and the growing demand for therapies that maintain efficacy after CDK4/6 inhibitor failure. The upcoming ASCO data and fast‑track regulatory pathway suggest that investors and clinicians alike should monitor gedatolisib’s progress closely.